These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 466931)

  • 1. Salicylate clearance, the resultant of protein binding and metabolism.
    Furst DE; Tozer TN; Melmon KL
    Clin Pharmacol Ther; 1979 Sep; 26(3):380-9. PubMed ID: 466931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration dependent plasma protein binding of salicylate in rheumatoid patients.
    Ekstrand R; Alvan G; Borga O
    Clin Pharmacokinet; 1979; 4(2):137-43. PubMed ID: 378501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose.
    Shen J; Wanwimolruk S; Purves RD; McQueen EG; Roberts MS
    J Pharmacokinet Biopharm; 1991 Oct; 19(5):575-95. PubMed ID: 1783992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers.
    Day RO; Graham GG; Bieri D; Brown M; Cairns D; Harris G; Hounsell J; Platt-Hepworth S; Reeve R; Sambrook PN
    Br J Clin Pharmacol; 1989 Dec; 28(6):695-702. PubMed ID: 2611090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zomepirac--aspirin interactions in man.
    Desiraju RK; Nayak RK; Pritchard JF
    J Clin Pharmacol; 1984; 24(8-9):371-80. PubMed ID: 6480878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Displacement of phenytoin from plasma binding sites by salicylate.
    Fraser DG; Ludden TM; Evens RP; Sutherland EW
    Clin Pharmacol Ther; 1980 Feb; 27(2):165-9. PubMed ID: 7353334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma protein binding interaction between valproic and salicylic acids in rhesus monkeys.
    Viswanathan CT; Levy RH
    J Pharm Sci; 1981 Nov; 70(11):1279-81. PubMed ID: 6795339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein binding of salicylate in uremic and normal plasma.
    Borgå O; Cederlöf IO; Ringberger VA; Norlin A
    Clin Pharmacol Ther; 1976 Oct; 20(4):464-75. PubMed ID: 975718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation.
    Sweeney KR; Chapron DJ; Brandt JL; Gomolin IH; Feig PU; Kramer PA
    Clin Pharmacol Ther; 1986 Nov; 40(5):518-24. PubMed ID: 3769383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease.
    Roberts MS; Rumble RH; Wanwimolruk S; Thomas D; Brooks PM
    Eur J Clin Pharmacol; 1983; 25(2):253-61. PubMed ID: 6628510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin.
    Greenblatt DJ; Abernethy DR; Boxenbaum HG; Matlis R; Ochs HR; Harmatz JS; Shader RI
    Arthritis Rheum; 1986 Aug; 29(8):971-80. PubMed ID: 3741521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central nervous system salicylate.
    Reed JR; Palmisano PA
    Clin Toxicol; 1975; 8(6):623-31. PubMed ID: 6188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salicylate protein binding in serum from young and elderly subjects as measured by diafiltration.
    Lesko LJ; Narang PK; Yeager L; Cutler NR
    Eur J Clin Pharmacol; 1985; 28(3):339-45. PubMed ID: 4007039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased protein binding of salicylates in Kawasaki disease.
    Koren G; Silverman E; Sundel R; Edney P; Newburger JW; Klein J; Robieux I; Laxer R; Giesbrecht E; Burns JC
    J Pediatr; 1991 Mar; 118(3):456-9. PubMed ID: 1999792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid fluorometric analysis of unbound salicylate in whole blood.
    Baselt RC; Stewart CB
    Res Commun Chem Pathol Pharmacol; 1976 Oct; 15(2):351-60. PubMed ID: 981790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats.
    Yu HY; Shen YZ; Sugiyama Y; Hanano M
    Drug Metab Dispos; 1990; 18(1):121-6. PubMed ID: 1970771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salicylate metabolite kinetics after several salicylates.
    Bochner F; Graham GG; Cham BE; Imhoff DM; Haavisto TM
    Clin Pharmacol Ther; 1981 Aug; 30(2):266-75. PubMed ID: 7249509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of salicylates: a re-assessment.
    Levy G
    Br J Clin Pharmacol; 1980 Oct; 10 Suppl 2(Suppl 2):285S-290S. PubMed ID: 7437270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects.
    Orr JM; Abbott FS; Farrell K; Ferguson S; Sheppard I; Godolphin W
    Clin Pharmacol Ther; 1982 May; 31(5):642-9. PubMed ID: 6804150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.